Two large observational studies published last year in the Journal of the American College of Cardiology (JACC) are raising questions about the need for β-blockers in all patients after a first heart attack. Both found a limited mortality benefit associated with use of β-blockers in certain clinical scenarios, underscoring the need for randomized clinical trials (RCTs) designed to test the effectiveness of these historical drugs in the contemporary era, the researchers said.